MedTrace Logo

The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.

NCT03927677 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2020-06-26

No results posted yet for this study

Summary

This is a Phase 1, open-label, fixed-sequence, 3-period, 2-way drug interaction study designed to assess the PK, PD, safety, and tolerability of LC350189 and colchicine when administered alone and in combination in healthy subjects.

Conditions

  • Gout
  • Hyperuricemia

Interventions

DRUG

Xanthine Oxidase Inhibitor

LC350189 200mg qd

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Study Design

Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-05
Primary Completion
2019-11-26
Completion
2019-11-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03927677 on ClinicalTrials.gov